A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Trial Profile

A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Vatelizumab (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 02 May 2016 The time frame of the primary endpoint (participants with Adverse Events) has changed from 62 to 68 weeks
    • 20 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 16 Jul 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top